News for 'Yesintek'

Biocon's Q2 net profit plunges 57% to Rs 56.7 cr; biosimilars launch to fuel stronger H2

Biocon's Q2 net profit plunges 57% to Rs 56.7 cr; biosimilars launch to fuel stronger H2

Rediff.com4 Nov 2026

Biocon Ltd reported a 57.3 per cent decline in consolidated net profit to Rs 56.7 crore for the September quarter of FY27, primarily due to a USD 20 million revenue recognition delay caused by geopolitical troubles, which is now expected to be booked in the third quarter.

Biocon eyes in-licensing to boost biosimilars portfolio, targets margin expansion

Biocon eyes in-licensing to boost biosimilars portfolio, targets margin expansion

Rediff.com9 May 2026

Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.

'Ready To Launch 5 products In 18 Months'

'Ready To Launch 5 products In 18 Months'

Rediff.com5 Jun 2025

'We recently launched Yesintek in the immunology space.'